Drugs / NI-1801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05403554 | Apr 2022 → May 2026 overdue | non-small cell lung carcinoma, ovarian endometrioid adenocarcinoma, pancreatic ductal adenocarcinoma, triple-negative breast carcinoma | Light Chain Bioscience - Novimmune SA | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NI-1801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05403554 ↗ |
| Target | CD47 | “NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody” NCT05403554 ↗ |